Thanks for your comments. I'm not claiming that selection bias has occurred in the Direct trial, but the opportunity for it may exist. If patients with slower progressing disease or longer life expectancy were selected it would skew the emerging picture of a very efficacious treatment that has been presented.
Flipper brought up a good point that several of the patients progressed very quickly which supports various claims that these patients were near the end. I know I sometimes play the skeptics advocate. If it does nothing more than reinforce the long thesis for myself or others by disproving doubts or misinformation I will consider it a success. Not all of us are scientists, MD's, or clinical trial experts, and it may take a few extra questions to figure this stuff out.
News 
Market Data 
Discover 
